A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
Abroad (travel likely)RecruitingPHASE1
Conditions
Systemic Lupus Erythematosus (SLE) · Rheumatoid Arthritis (RA)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Investigational Site Number : 001-203, Brisbane, Queensland, Australia
Investigational Site Number : 001-201, Melbourne, Victoria, Australia
Investigational Site Number : 001-401, Sarajevo, Bosnia and Herzegovina
Investigational Site Number : 001-301, Auckland, New Zealand
Investigational Site Number : 001-801, Pretoria, South Africa
Investigational Site Number : 001-803, Pretoria, South Africa
Investigational Site Number : 001-804, Vereeniging, South Africa
Study leads
Clinical Sciences & Operations
Study Director
Sanofi